This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Total Patient Care in IBD: New Options for Treatment and Current Recommendations for Health Maintenance

Total Patient Care in IBD: New Options for Treatment and Current Recommendations for Health Maintenance

Format

Roundtable

Time to Complete

1.50 hours

Released

October 15, 2018

Expires

October 15, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditTM
1.38 / CNE Contact Hour (1.38 of which is eligible for pharmacology credit)
1.50 / CE for Pharmacists (0.15 CEU)

Accredited Provider



CME/CNE accreditation provided by Boston University School of Medicine and CE for pharmacists is provided by The University of Rhode Island College of Pharmacy

Commercial Supporter

This activity is supported by an independent educational grant from Pfizer Inc.

Program Description

Utilizing an expert multidisciplinary faculty team and featuring video vignettes of ideal patient education encounters, this activity is designed to address several key issues. These issues include, but are not limited to: Gastroenterology (GI) clinicians may not be familiar with newer and emerging agents for the treatment of IBD in patients who are unable to achieve remission with other therapies; Patients with IBD are at increased risk for preventable disease and infection, yet they do not receive preventive services and vaccines at the same rate as the general population; Clinicians managing IBD patients may not have awareness of vaccine guidelines for patients with IBD.

This program will address knowledge, competence, and practice gaps among clinician members of the IBD care team. Clinicians involved in the treatment of IBD patients need an in-depth understanding of treatment modalities that target previously unfamiliar areas in the inflammatory pathway and how they can integrate those into practice and into the best possible individualized care. Education is also needed to reverse the trend of low vaccination and screening rates in IBD. Clinicians should be aware of the risk of preventable disease, guideline recommendations for vaccination in immunocompetent and immunosuppressed IBD patients, and the possible consequences for patients who do not receive these services.

By utilizing evidence-based tools and practical, real-world patient cases, providers will gain a clearer understanding of the deficits in vaccination and the harm that can come to patients because of low vaccination rates.

Intended Audience

Gastroenterologists, gastroenterology fellows, primary care physicians, NP/PAs, nurses, pharmacists and others who manage/treat patients with IBD

Educational Objectives

Upon completion of these activities, participants should be better able to:

  • Discuss novel agents that are available and those in clinical trials for IBD in terms of therapeutic target, safety, and efficacy.
  • Examine the risk of infection and various comorbidities in patients with IBD and the consequences of increased prevalence of these conditions.
  • Discuss current rates for preventive services and vaccination in patients with IBD, barriers to these services, and strategies that the healthcare team can employ to overcome barriers.
  • Explore current guideline recommendations for vaccination and health screening in patients with IBD focusing on updates and new vaccines.

Conflict Of Interest Disclosure Policy

The Boston University School of Medicine and University of Rhode Island College of Pharmacy ask all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME), Continuing Nursing Education (CNE) and Continuing Pharmacy Education (CPE), activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CE activity participants prior to the start of the educational activity. Boston University School of Medicine and University of Rhode Island have procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty

Dr. Farraye is a consultant for Braintree Laboratories, Janssen Biotech, Inc., Merck & Co.,Inc., Pfizer Inc., and Takeda Pharmaceuticals, USA, Inc. He also is a stockholder and on the advisory board for Innovation Pharmaceuticals and is on the data safety management board for Eli Lilly and Company and Theravance Biopharma.

Ms. Beth-Ann Norton is a consultant for Takeda Pharmaceuticals, USA, Inc.

Ms. Toni Zahorian has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Michael Burk, Senior Program Manager for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Carmela Townsend, Lead Nurse Planner, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Dana Frazier, Program and Grant Manager for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Mary-Jane Kanaczet, M.Ed, Director of the Office of Continuing Professional Development College of Pharmacy, the University of Rhode Island, has no relevant financial relationships to disclose.

Bret Lashner, MD, planning committee member for Boston University School of Medicine’s Office of Continuing Medical Education and Professor of Medicine at the Cleveland Clinic, has no relevant financial relationships to disclose.

Beth-Ann Norton, CNE Course Advisor, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Laura Stinson, consultant medical editor for Boston University School of Medicine’s Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

Boston University School of Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.38

Type

CNE Contact Hour(s)

Accreditation Statement

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

CNE Contact Hours: 1.38, all of which is eligible for pharmacology credit.

Credit

1.50

Type

CE for Pharmacists

Accreditation Statement

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

This is a knowledge-based educational activity. Pharmacists will receive 1.50 Contact Hours (0.15 CEUs) for the home study program. No partial credit will be given. Release Date 10/15/18.

Universal Activity Number (UAN): 0060-9999-18-036-H01-P

Disclosure of Unlabeled Use

The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

Instructions for CME and CNE Continuing Education Credits

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.50 AMA PRA Category 1 Credit and nurses are entitled to receive 1.38 CNE contact hours. Statements of credit will be available to print immediately. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians and nurses who successfully complete the post-test and evaluation will respectively receive CME. You must score with a 70% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

For any CME or CNE accreditation questions please email the BUSM CME office at cme@bu.edu.

Instructions for Completing a Program Evaluation and Reporting Pharmacy CE Credit

Program Evaluation
All participants will have the opportunity to evaluate the educational session, speakers and identify future educational needs.

Requirements for CE Credit
A program evaluation must be completed at www.uripharmacycpd.org within 60 days of the program completion date in order to receive CE credit. CE credit will be transferred to the CPE Monitor upon successful completion of the program evaluation. Transfer of CE credit should be verified at mycpemonitor.net where CE statements are available to print. Please refer to the evaluation instructions that follow for completing program evaluations and reporting CE credit.

Instructions for Completing a Program Evaluation and Reporting Pharmacy CE credit

1. Go to the University of Rhode Island College of Pharmacy Continuing Professional Development Learning Management System located at www.uripharmacycpd.org and create an account using your email address and pharmacy license number.* Enter all of the required account information. Verify that your date of birth and NABP ID Number are entered correctly. Click the “Update Account” button at the bottom of the page to save the account information.

2. Complete the program evaluations. Evaluations must be completed within 60 days of the program.
  • Participants in the online enduring activity should click on Available Online Activities and select the program title of the activity. Select post-test.
  • Enter the program evaluation code.
  • Complete the evaluation and click “submit.”
  • You will receive a confirmation message of evaluation completion and notification that your CE data was reported to the CPE Monitor.

The access code for this enduring program Total Patient Care in IBD: New Options for Treatment and Current Recommendations for Health Maintenance is TBD58

Please note: ACPE will only accept CPE data that is reported by providers within 60 days of the live program date. CPE data is reported immediately upon your completion of this evaluation although it may take 48-72 hours to appear in your CPE Monitor profile. You will be notified of any problems transmitting your participant data via email. Most transmission problems are related to errors in transcribing date of birth and/or NABP ID number. It is strongly recommended that you check your profile in the CPE Monitor to verify your participation in this program has been reported.

*Your pharmacy license number, date of birth and NABP ID number are required to create an account in the URI CPD online registration and evaluation system in order to report participant data to the CPE Monitor. Pharmacy license numbers will not be used for any other purpose.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue